Quick Take

The FDA has issued a warning letter to Guangzhou Huli Technology Co., Ltd., doing business as Fantasy Face, for marketing and selling unapproved new drugs over the internet. The enforcement action, identified as reference number 722228, targets products that have bypassed the mandatory regulatory review process for safety and efficacy.

Why It Matters

This action is part of a critical regulatory push to curb the sale of 'cosmeceuticals'—often eyelash or eyebrow growth serums—that contain active pharmaceutical ingredients without a prescription or FDA oversight. For eye care providers, these unregulated products are a frequent source of hidden ocular side effects, including inflammation and periorbital changes, which patients may not associate with their beauty routine. Monitoring such warnings helps clinicians identify the source of otherwise idiopathic ocular surface issues in patients purchasing enhancers from international online retailers.

Key Details

• The FDA identified Guangzhou Huli Technology Co., Ltd. (dba Fantasy Face) for distributing unapproved new drugs via online platforms.
• The warning letter (Reference #722228) cites violations of the Federal Food, Drug, and Cosmetic Act regarding the sale of products that lack required safety and effectiveness data.
• The products were marketed directly to consumers, bypassing the traditional medical consultation and prescription process.
• The enforcement highlights the FDA's continued focus on international manufacturers selling into the U.S. market through digital storefronts.

Practice Implications

Clinicians should maintain a high index of suspicion for unapproved drug use in patients presenting with unexplained blepharitis, conjunctival hyperemia, or iris color changes. It is advisable to specifically ask patients about internet-purchased lash or brow enhancers, such as those from Fantasy Face, and educate them on the potential risks of using products that have not been vetted by the FDA.

Who's Affected

What's Next

The manufacturer is expected to respond to the FDA's concerns and bring their products into compliance or risk further actions such as import alerts or product seizures. Eye care professionals should monitor for updates to the FDA's warning letter database to stay informed about other unapproved ophthalmic 'cosmetics' entering the market.